Molecular Mechanisms of Cancer
- Institution
- University of Chicago, IL
- Principal investigator
- Barbara L. Kee
- Funding
- $213K
- Duration
- 1997–2029
Moonbase score
Still being scored
Abstract
The overarching goal of the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) Molecular Mechanisms of Cancer (MMC) Program is to catalyze collaborative efforts that leverage emerging scientific discoveries from the laboratories of MMC scientists and propel them in a translational direction that makes an impact on cancer prevention, diagnosis, and treatment for patients living in our catchment area and beyond. The University of Chicago is a hotbed of scientific innovation, and the MMC continues to maximize the health benefits that emerge from this science, informed by regional cancer burden trends. The MMC Program is centered on three key scientific and cancer-focused research themes: (1) deregulated gene expression and epigenetic defects in cancer; (2) altered cell growth and transformation; and (3) the tumor microenvironment in tumor growth and metastasis. These intersecting themes encompass the research of all members, across organ sites. The breadth and multi-disciplinary nature of our research contributes to the success of MMC in establishing productive translational collaborations both within MMC and across the other UCCCC programs. The MMC Program consists of 51 faculty members from 13 Departments, including 14 talented new faculty recruited to the institution in this funding cycle. In addition to increasing membership by 38% in this cycle, we increased the number and percentage of high-impact publications from 20% to 38% of total publications, increased NCI funding from $3.5M to $5M and launched 6 new working groups and multiple team science initiatives. Importantly, we have had increased success in moving our cutting-edge science into clinical trials, clinical applications, and/or commercialization. MMC leadership has fostered these successes by enhancing inter-programmatic collaborations, particularly with the UCCCC Clinical & Experimental Therapeutics Program via new working groups and targeted funding. Programmatic activities are informed by regional cancer burden trends and designed to reduce incidence and improve outcomes through the translation of laboratory-based insights into clinical strategies. Faculty engagement in scientific dissemination and public education has supported regional outreach goals. In the next cycle, the MMC will continue to support institutional efforts that strengthen research environments, attract high-caliber investigators, and provide structured mentoring and training to early-career cancer researchers.
LOADING MOONBASE SCORE
Questions for University of Chicago
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of ChicagoNot yet scored
BATF as an inducible regulator of natural killer cell expansion and effector function
Barbara L. Kee · $550K · 2025–2030
- NIH · University of Chicago66
Host's and microbiota's contribution to sexual dimorphism of autoimmunity
Alexander V Chervonsky · $643K · 2017–2027
- NIH · University of Chicago57
From synapses to neural representations: The role of neuromodulatory circuits in shaping contextual memories in the hippocampus
Mark E J Sheffield · $584K · 2022–2027